BAT1806 · Tofidence

Monoclonal antibody

Biosimilar of tocilizumab

Approvedregulatory verdict

Evidence outlook

Approved: Rheumatoid Arthritis, COVID-19

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (5)
US
  • Giant Cell Arteritis (GCA) TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of giant cell arteritis (GCA) in adult patients.Outside this platform's coverageFDA label
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA) TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.Outside this platform's coverageFDA label
  • Cytokine Release Syndrome (CRS) TOFIDENCE (tocilizumab-bavi) is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome in adults and pediatric patients 2 years of age and older.
    Outside this platform's coverageFDA label
  • Patients 2 years of age and older with active systemic juvenile idiopathic arthritisFDA label
Product first approved 2023
EU
  • Tocilizumab STADA (previously Tofidence), biosimilar of RoActemra: rheumatoid arthritis (moderate to severe active RA after DMARDs or TNF blockers; severe progressive RA not previously treated with methotrexate), systemic juvenile idiopathic arthritis, juvenile idiopathic polyarthritis, and COVID-19 in adults on systemic corticosteroids who need oxygen or ventilation.
Product first approved 2024EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Rheumatoid Arthritis
Phase 1 (3)
Rheumatoid Arthritis
NCT03606876 · Bio-Thera Solutions
2018-06-13 – 2019-07-17 · Rheumatoid Arthritis
What this study did
Other / comorbidity

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for COVID-19: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
BAT1806 (Tofidence): this drugApprovedMonoclonal antibodyIL-6 receptornot yet gradedNo reviewed efficacy summary in this indication
Baricitinib (Olumiant)ApprovedSmall moleculeJAK, JAK1/2not yet gradedNo reviewed efficacy summary in this indication
CT-P47 (tocilizumab) (Avtozma)ApprovedMonoclonal antibodyIL-6R antagonistnot yet gradedNo reviewed efficacy summary in this indication
Elasomeran (Spikevax)ApprovedVaccineSARS-CoV-2 spike proteinReliable signalNo reviewed efficacy summary in this indication
Tocilizumab (Actemra / RoActemra)ApprovedMonoclonal antibodyIL-6 receptorPartial signal
NCT04409262: Time to Hospital Discharge or "Ready for Discharge" up to Day 28 (Up to Day 28): Remdesivir + Placebo (RDV+Placebo) - mITT Population 14 days (95% CI 11 to 16) | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population 14 days (95% CI 12 to 15) missed
NCT04372186: Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28 (Up to Day 28): Tocilizumab 12.04 Percentage of Participants (95% CI 8.52 to 16.86) | Placebo 19.26 Percentage of Participants (95% CI 13.34 to 27.36)
Azvudine (FNC)Phase 3Small moleculeHIV reverse transcriptasenot yet gradedNo reviewed efficacy summary in this indication
IbuzatrelvirPhase 3Small moleculeSARS-CoV-2 3CL proteasenot yet gradedNo reviewed efficacy summary in this indication
Levilimab (Ilsira)Phase 3Monoclonal antibodyIL-6 receptornot yet gradedNo reviewed efficacy summary in this indication
MasitinibPhase 2Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesnot yet gradedNo reviewed efficacy summary in this indication
GSK4396687
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.